SUPRIYA LIFESCIENCE IPO LTD.
It is engaged in the manufacturing of Active pharmaceutical ingredients (APIs) and produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, and anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in terms of volume.
It has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company’s manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.
Satish Waman Wagh is the company promoter.
|Particulars||For the year/period ended (₹ in Millions)|
|Profit After Tax||659.59||1,238.28||733.74||394.24|
- Funding capital expenditure requirements of the company.
- Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the company.
- General corporate purposes.
|IPO Opening Date||Dec 16, 2021|
|IPO Closing Date||Dec 20, 2021|
|Issue Type||Book Built Issue IPO|
|Face Value||₹2 per equity share|
|IPO Price||₹265 to ₹274 per equity share|
|Market Lot||54 Shares|
|Min Order Quantity||54 Shares|
|Listing At||BSE, NSE|
|Issue Size||[.] Eq Shares of ₹2
(aggregating up to ₹700.00 Cr)
|Fresh Issue||[.] Eq Shares of ₹2
(aggregating up to ₹200.00 Cr)
|Offer for Sale||[.] Eq Shares of ₹2
(aggregating up to ₹500.00 Cr)
|IPO Open Date||Dec 16, 2021|
|IPO Close Date||Dec 20, 2021|
|Basis of Allotment Date||Dec 23, 2021|
|Initiation of Refunds||Dec 24, 2021|
|Credit of Shares to Demat Account||Dec 27, 2021|
|IPO Listing Date||Dec 28, 2021|
IPO Lot Size
IPO Promoter Holding
- Pre Issue Share Holding 99.98%
- Post Issue Share Holding 68.24%
Its product portfolio diversified across different therapeutic segments so it has been getting strong demand.
The IPO is handled by merchant bankers ICICI Securities and Axis Capital, while Link In time India is the registrar to the offer.